If you can still get excited about diabetes research headlines, then here’s some exciting news coming out of Cambridge, Mass, this week: Tolerx, a life sciences company, has reported they are in Phase 3 clinical trials for a new treatment of type 1 diabetes. If everything goes to plan, a representative of the company says, Tolerx could launch the first-ever offering approved by the FDA to treat the cause of type 1 diabetes. Pretty cool!…Read more »
The high-powered diabetic cycling group Team Type 1 has once again pulled off a jaw-dropping feat: they’ve somehow caught the attention of 23andMe, one of just three celeb-status companies in the world offering “personal genomics services” — they scan people’s DNA for details on their ancestry and individual health risks — and convinced them to launch a probe into Type 1 and Type 2 diabetes.
This research could provide unprecedented insights into the genes that…
When the JDRF recently announced its newest artificial pancreas push — a partnership with Animas and Dexcom to actually develop a commercial product — head of the project Aaron Kowalski kindly agreed to answer reader questions here.
Today, I bring you those answers, direct “from the horses’ mouth,” as it were.
Q) How much more advanced will this be than the Medtronic Paradigm Veo system launched in Europe, which stops insulin delivery for…
Living in the United States, we are often stuck in a bubble of US-centric news. This is true for diabetes as much as any other topic. But as World Diabetes Day attests to, diabetes is hardly just an American thing. In reality, there’s much more going on in the global diabetes research arena than you might think (since our media announcements are pretty much limited to, err, Boston, Miami and the Bay Area). So today,…Read more »
Apropos to last week’s post on Testing Driving Insulin, I was thinking about the ‘older’ versions — and discovered a reader letter I received back in February of 2006. It seems just as timely today, considering that research supported the case for continuing to offer patients the option of animal insulin:
“In our systematic review we could not identify substantial differences in the safety and efficacy between insulin species. Many important patient-oriented outcomes like health-related…